Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering | Synapse

August 1, 2024Open Access

Ver artículo completo

The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering

MOMichelle L. O’DonoghueGeneral Cardiology

Robert S. RosensonGeneral / Preventive / Lipids JLJ. Antonio G. LópezUniversity of Central Florida

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Olpasiran, a small interfering RNA (siRNA), blocks lipoprotein(a) (Lp(a)) production by preventing translation of apolipoprotein(a) mRNA. In phase 2, higher doses of olpasiran every 12 weeks (Q12W) reduced circulating Lp(a) by >95%.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

O’Donoghue et al. (Thu,) studied this question.

synapsesocial.com/papers/68e5dc44b6db643587571785 https://doi.org/https://doi.org/10.1016/j.jacc.2024.05.058

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease2022 · 538 citations
2Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation2023 · 186 citations
3Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality2009 · 1,734 citations
4Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)2022 · 96 citations
5RNA Interference: Biology, Mechanism, and Applications2003 · 1,308 citations